Market capitalization | $40.85m |
Enterprise Value | $-1.45m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.06 |
EV/Sales (TTM) EV/Sales | -0.23 |
P/S ratio (TTM) P/S ratio | 6.35 |
P/B ratio (TTM) P/B ratio | 0.56 |
Revenue growth (TTM) Revenue growth | -11.92% |
Revenue (TTM) Revenue | $6.43m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
1 Analyst has issued a forecast Co-Diagnostics, Inc.:
1 Analyst has issued a forecast Co-Diagnostics, Inc.:
Dec '23 | |
Current assets | 62 62 |
Fixed assets | 42 42 |
Total Assets | 104 104 |
Dec '23 | |
Equity | 86 86 |
Debt capital | 18 18 |
Total Capital | 104 104 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Co-Diagnostics, Inc. engages in the development, manufacture, and marketing of diagnostics technology. It offers design services, vector control, equipment, diagnostic, and research solutions. The company was founded by Brent C. Satterfield and Dwight H. Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.
Head office | United States |
CEO | Dwight Egan |
Employees | 155 |
Founded | 2013 |
Website | www.codiagnostics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.